Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation

Background: There is limited data on the relative survival rate of first-line therapy of gefitinib, erlotinib (first-generation epidermal growth factor receptor-tyrosine kinase inhibitor [EGFR-TKI]), and afatinib (second-generation EGFR-TKI) in patients with EGFR-mutated advanced lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Po-Yen, Wang, Chin-Chou, Hsu, Chien-Ning, Chen, Chung-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382571/
https://www.ncbi.nlm.nih.gov/pubmed/34434112
http://dx.doi.org/10.3389/fphar.2021.720687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382571/
https://www.ncbi.nlm.nih.gov/pubmed/34434112
http://dx.doi.org/10.3389/fphar.2021.720687

Ejemplares similares